UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Life Sciences & Biomedicine | Oncology | Science & Technology | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis | Index Medicus
Journal Article
Journal of neurosurgery, ISSN 0022-3085, 01/2015, Volume 122, Issue 1, pp. 4 - 23
meningioma | STR = subtotal resection | EBRT = external beam radiation therapy | RANO = Response Assessment in Neuro-Oncology | RTOG = Radiation Therapy Oncology Group | PFS = progression-free survival | EORTC = European Organisation for Research and Treatment of Cancer | CGE = cobalt gray equivalent | GTR = gross-total resection | SRS = stereotactic radiosurgery | oncology | NF2 = neurofibromatosis Type 2 | MEN1 = multiple endocrine neoplasia Type 1 | outcomes | radiotherapy | surgery | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Surgery | Science & Technology | Disease-Free Survival | Humans | Meningioma - surgery | Brain Neoplasms - therapy | Treatment Outcome | Combined Modality Therapy | Brain Neoplasms - surgery | Meningioma - therapy | Index Medicus | Abridged Index Medicus | Radiotherapy | Meningioma | Outcomes
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2013, Volume 31, Issue 31, pp. 3971 - 3979
Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Procarbazine - administration & dosage | Chemoradiotherapy - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Time | Cytarabine - adverse effects | Cranial Irradiation - methods | Lymphoma - mortality | Lymphoma - therapy | Vincristine - administration & dosage | Adult | Female | Rituximab | Central Nervous System Neoplasms - therapy | Treatment Outcome | Cranial Irradiation - adverse effects | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Central Nervous System Neoplasms - mortality | Index Medicus | Original Reports
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2012, Volume 48, Issue 14, pp. 2192 - 2202
Hematology, Oncology and Palliative Medicine | Brain tumour | Chemotherapy | Randomised trial | Glioblastoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Pharmacology. Drug treatments | Tumors | United States | Humans | Middle Aged | Brain Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Young Adult | Karnofsky Performance Status | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Brain Neoplasms - mortality | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Brain Neoplasms - drug therapy | Glioblastoma - therapy | Disease-Free Survival | Magnetic Resonance Imaging | Electric Stimulation Therapy - adverse effects | Glioblastoma - pathology | Brain Neoplasms - therapy | Quality of Life | Aged | Israel | Glioblastoma - drug therapy | Glioblastoma - mortality | Medical colleges | Neurosciences | Brain tumors | Clinical trials | Glioblastoma multiforme | Biometry | Cancer | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 12/2008, Volume 26, Issue 34, pp. 5610 - 5617
Neurology | Biological and medical sciences | Medical sciences | Tumors of the nervous system. Phacomatoses | Tumors | Snake Venoms - therapeutic use | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Disease-Free Survival | Maximum Tolerated Dose | Peptides, Cyclic - antagonists & inhibitors | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Glioblastoma - drug therapy | Index Medicus
Journal Article
Neuro-oncology (Charlottesville, Va.), ISSN 1522-8517, 02/2019, Volume 21, Issue 2, pp. 234 - 241
meningioma | volume | MRI | response | survival | Oncology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Magnetic Resonance Imaging - methods | Male | Response Evaluation Criteria in Solid Tumors | Treatment Outcome | Combined Modality Therapy | Tumor Burden | Disease Progression | Meningeal Neoplasms - therapy | Meningioma - therapy | Young Adult | Meningioma - pathology | Adolescent | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Meningeal Neoplasms - pathology | Child | Observer Variation | Index Medicus | Life Sciences | Clinical Investigations
Journal Article
Lancet neurology, ISSN 1474-4422, 2010, Volume 9, Issue 1, pp. 67 - 76
Journal Article
Journal of neuro-oncology, ISSN 0167-594X, 9/2018, Volume 139, Issue 3, pp. 781 - 783
Medicine & Public Health | Neurology | Oncology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Prognosis | Bone Neoplasms - therapy | Humans | Neoplasm Recurrence, Local - therapy | Bone Neoplasms - secondary | Male | Survivorship | Meningeal Neoplasms - therapy | Meningioma - therapy | Neoplasm Recurrence, Local - pathology | Young Adult | Meningioma - pathology | Adult | Meningeal Neoplasms - pathology | Survival | Meningioma | Metastases
Journal Article
Cancer, ISSN 0008-543X, 06/2020, Volume 126, Issue 12, pp. 2821 - 2828
bevacizumab | trebananib | glioblastoma | angiogenesis | angiopoietin | Life Sciences & Biomedicine | Oncology | Science & Technology | Fc receptors | Randomization | Toxicity | Glioblastoma | Fusion protein | Vascular endothelial growth factor | Survival | Growth factors | Bevacizumab | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 10/2007, Volume 25, Issue 30, pp. 4730 - 4735
Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Procarbazine - administration & dosage | Prospective Studies | Humans | Middle Aged | Male | Central Nervous System Neoplasms - radiotherapy | Lymphoma - drug therapy | Central Nervous System Neoplasms - immunology | Immunotherapy | Vincristine - administration & dosage | Adult | Female | Lymphoma - radiotherapy | Antibodies, Monoclonal, Murine-Derived | Lymphoma - immunology | Rituximab | Treatment Outcome | Combined Modality Therapy | Cranial Irradiation | Remission Induction | Cytarabine - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Central Nervous System Neoplasms - drug therapy | Index Medicus
Journal Article
Journal of neuro-oncology, ISSN 0167-594X, 08/2005, Volume 74, Issue 1, pp. 77 - 86
glioblastoma multiforme | mutation | Medicine & Public Health | epidermal growth factor receptor | survival | Oncology | erlotinib hydrochloride (HCl) | gefitinib | chemotherapy | Chemotherapy | Mutation | Gefitinib | Erlotinib hydrochloride (HCl) | Glioblastoma multiforme | Survival | Epidermal growth factor receptor | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Neurology | Biological and medical sciences | Medical sciences | Tumors of the nervous system. Phacomatoses | Immunomodulators | Pharmacology. Drug treatments | Erlotinib Hydrochloride | Animals | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Humans | Receptor, Epidermal Growth Factor - drug effects | Signal Transduction - physiology | Clinical Trials as Topic | Brain Neoplasms - drug therapy | Glioblastoma - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article